Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Stock Holding Pvt Ltd27-03-2017
27-03-2017
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for VAM Holdings Ltd27-03-2017
Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Consumer Pvt Ltd22-03-2017
Jubilant Life Sciences likely to buy speciality pharma biz in US
Jubilant Life Sciences' subsidiary Jubilant Pharma will negotiate a potential acquisition of a speciality business in the US. The board of directors of Jubilant Pharma Ltd, a material...21-03-2017
Updates
Sub: Disclosure under Regulation 30(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended The Board of Directors of Jubilant Pharma Limited ('JPL'), a material wholly owned subsidiary of the Company in Singapore, has approved to negotiate a potential acquisition of a specialty pharma business in the United States using only internal accruals, , subject to due diligence, satisfactory agreements, etc. and its...21-03-2017
Closure of Trading Window
Pursuant to the Company's Code of Conduct for Prevention of Insider Trading, the Trading Window for dealing in the securities of the Company will be closed for Designated Persons' from Friday, March 24, 2017 and the same shall remain closed till 48 hours after the announcement of the financial results for the quarter ending March 31, 2017 to the Stock Exchanges. Accordingly, the Designated Persons have been intimated not to trade in the securities...15-03-2017
Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Jubilant Stock Holding Pvt Ltd06-03-2017
Intimation of Schedule of Investor / Analyst Meetings
Jubilant Life Sciences Ltd has informed BSE regarding "Intimation of Schedule of Investor / Analyst Meetings".28-02-2017
Issuance of Commercial Papers of Rs. 40 crore
Jubilant Life Sciences Ltd has informed BSE that the Company has issued Commercial Papers (CPs') of Rs. 40 crore on February 28, 2017.28-02-2017
Jubilant gets USFDA nod for generic anti-fungal capsules
Jubilant Life Sciences has received approval from the US health regulator to market generic Sporanox capsules, used for treating fungal infections, in the American market. The company has...27-02-2017